Page 1 of 1INSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.1. Company Name and Address4. EPA ProductRegistrationOMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460DATA CALL-IN RESPONSE3. Date and Type of DCI and NumberPRODUCT SPECIFIC03-Mar-2008ID # PDCI-098901-275492. Case # and Name3026 Benzisothiazolin-3-oneChemical # and Name0989011,2-Benzisothiazolin-3-one5. I wish tocancel thisproduct registration voluntarily6. Generic Data7. Product Specific Data7a. My product is an MUP andI agree to satisfy the MUPrequirements on the attachedform entitled "RequirementsStatus and Registrant'sResponse."7b. My product is an EUP andI agree to satisfy the EUPrequirements on the attachedform entitled "RequirementsStatus and Registrant'sResponse."6a. I am claiming a GenericData Exemption because Iobtain the active ingredientfrom the source EPA registration number listed below.6b. I agree to satisfy GenericData requirements as indicatedon the attached form entitled"Requirements Status andRegistrant's Response."N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.10. Name of Company11. Phone Number9. Date8. Certification I certify that the statements made on this form and all attachments are true, accurate, and complete. I acknowledge that anyknowingly false or misleading statement may be punishable by fine, imprisonment or both under applicable law.Signature and Title of Company's Authorized Representative__________________________________INSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 1 of 4OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #PRODUCT SPECIFIC2. Case # and Name3026 Benzisothiazolin-3-oneEPA Reg. No.8. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321DD-MMM-YYYYPDCI-098901-NNNNNNNNNN-NNNNND R A F T C O P YProduct Chemistry Data Requirements (Antimicrobial)(29)830.15508EPEE, K, M, Q, XProduct Identity and composition(30)830.16008EPEE, K, M, Q, XDescription of materials used to produce the product(31)830.16208EPEE, K, M, Q, XDescription of production process(32)830.16508EPEE, K, M, Q, XDescription of formulation process(33)830.16708EP & possibly TGAIEE, K, M, Q, XDiscussion of formation of impurities(34 ,35 ,36)830.17008EP & possibly TGAIEE, K, M, Q, XPreliminary analysis(37)830.17508EPEE, K, M, Q, XCertified limits(38)830.18008EPEE, K, M, Q, XEnforcement analytical method(15)830.63028TGAIEE, K, M, Q, XColor(17)830.63038TGAI & EPEE, K, M, Q, XPhysical state(18)830.63048TGAIEE, K, M, Q, XOdor12. Name of Company13. Phone NumberSignature and Title of Company's Authorized Representative__________________________________10. Certification I certify that the statements made on this form and all attachments are true, accurate, and complete. Iacknowledge that anyknowingly false or misleading statement may be punishable by fine, imprisonment or both under applicable law11. DateINSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 2 of 4OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #PRODUCT SPECIFIC2. Case # and Name3026 Benzisothiazolin-3-oneEPA Reg. No.8. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321DD-MMM-YYYYPDCI-098901-NNNNNNNNNN-NNNNND R A F T C O P Y(8 ,9)830.63138TGAIEE, K, M, Q, XStability to normal and elevated temperatures,metals, and metal ions(10)830.63148EPEE, K, M, Q, XOxidizing or reducing action(11)830.63158EPEE, K, M, Q, XFlammability(12)830.63168EPEE, K, M, Q, XExplodability830.63178EPEE, K, M, Q, XStorage stability(14)830.63198EPEE, K, M, Q, XMiscibility830.63208EPEE, K, M, Q, XCorrosion characteristics(16)830.63218EPEE, K, M, Q, XDielectric breakdown voltage(6 ,7)830.70008TGAI & EPEE, K, M, Q, XpH830.70508TGAIEE, K, M, Q, XUV/Visible absorption(13)830.71008EPEE, K, M, Q, XViscosity(19 ,20)830.72008TGAI or PAIEE, K, M, Q, XMelting point/melting rangeInitial to indicate certification as to information on this page (fulltext of certification is on page one).DateINSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 3 of 4OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #PRODUCT SPECIFIC2. Case # and Name3026 Benzisothiazolin-3-oneEPA Reg. No.8. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321DD-MMM-YYYYPDCI-098901-NNNNNNNNNN-NNNNND R A F T C O P Y(21 ,22)830.72208TGAI or PAIEE, K, M, Q, XBoiling point/boiling range(23 ,24)830.73008TGAI & EPEE, K, M, Q, XDensity/relative density(2 ,3)830.73708TGAI or PAIEE, K, M, Q, XDissociation constants in water(4)830.75508TGAI or PAIEE, K, M, Q, XPartition coefficient (n-octanol/water), shake flaskmethod(5)830.75708TGAI or PAIEE, K, M, Q, XPartition coefficient (n-octanol/water), estimation byliquid chromatography(25)830.78408TGAI or PAIEE, K, M, Q, XWater solubility: Column elution method, shake flaskmethod(26)830.78608TGAI or PAIEE, K, M, Q, XWater solubility, generator column method(27 ,28)830.79508TGAI or PAIEE, K, M, Q, XVapor pressureToxicology Data Requirements (Antimicrobial)(51 ,52)870.11008EP; MP; TGAIEE, K, M, Q, XAcute Oral Toxicity(1 ,39 ,40)870.12008EP; MP; TGAIEE, K, M, Q, XAcute dermal toxicity(47 ,48 ,49,50)870.13008EP; MP; TGAI/EPEE, K, M, Q, XAcute inhalation toxicityInitial to indicate certification as to information on this page (fulltext of certification is on page one).DateINSTRUCTIONS: Please type or print in ink. Please read carefully the attached instructions and supply the information requested on this form.Use additional sheet(s) if necessary.4. GuidelineRequirementNumber5. Study Title1. Company Name and AddressPage 4 of 4OMB Approval 2070-0107OMB Approval 2070-0057United States Environmental ProtectionAgency Washington, D.C. 20460REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE3. Date and Type of DCI and NumberID #PRODUCT SPECIFIC2. Case # and Name3026 Benzisothiazolin-3-oneEPA Reg. No.8. TimeFrame(Months)9. RegistrantResponse7. TestSubstance6. UsePatternPROTOCOLProgressReports321DD-MMM-YYYYPDCI-098901-NNNNNNNNNN-NNNNND R A F T C O P Y(41 ,42 ,43,44)870.25008EP; MP; TGAI/EP; TGAIEE, K, M, Q, XAcute dermal irritation(45 ,46)870.26008EP; MP; TGAIEE, K, M, Q, XSkin sensitization870.24008EE, K, M, Q, XAcute eye irritationInitial to indicate certification as to information on this page (fulltext of certification is on page one).DateCase # and Name:3026 Benzisothiazolin-3-oneDCI Number:PDCI-098901-27549Page 1 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSTGAI & EP = Technical Grade of the Active Ingredient and End-Use Product; EP; MP; TGAI = End Use Product; Manufacturing Use Product; Technical Grade Active Ingredient; TGAI or PAI =Technical Grade of the Active Ingredient or Pure Active Ingredient; EP = End Use Product [EP]; TGAI = Technical Grade Active Ingredient [TGAI]; EP; TGAI = End Use Product; Technical GradeActive Ingredient; EP & possibly TGAI = End- Use Product and possibly Technical Grade Active IngredientUse Categories Key:K -M -Q -ResidentialIndoor nonfood useResidential outdoor useX -EE -Materials preservativesIndoor use1For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.2If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).3Required when the test substance contains an acid or base functionality (organic or inorganic) or an alcoholic functionality (organic).4Required if the TGAI or PAI is organic and non-polar.5Required if the TGAI or PAI is organic and non-polar.6If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).7Required if the product is dispersible with water.8If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).9Data on the stability to metals and metal ions is required only if the active ingredient is expected to come in contact with either material during storage.10Required if the product contains an oxidizing or reducing agent11Required when the product contains combustible liquids.12Required when the product is potentially explosive.13Required if the product is a liquid.14Required if the product is an emulsifiable liquid and is to be diluted with petroleum solvents.15If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).Case # and Name:3026 Benzisothiazolin-3-oneDCI Number:PDCI-098901-27549Page 2 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSTGAI & EP = Technical Grade of the Active Ingredient and End-Use Product; EP; MP; TGAI = End Use Product; Manufacturing Use Product; Technical Grade Active Ingredient; TGAI or PAI =Technical Grade of the Active Ingredient or Pure Active Ingredient; EP = End Use Product [EP]; TGAI = Technical Grade Active Ingredient [TGAI]; EP; TGAI = End Use Product; Technical GradeActive Ingredient; EP & possibly TGAI = End- Use Product and possibly Technical Grade Active Ingredient16Required if the end-use product is a liquid and is to be used around electrical equipment.17If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).18If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).19If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).20Required when the TGAI is solid at room temperature.21If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).22Required if the TGAI is liquid at room temperature.23If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).24True density or specific density are required for all test substances. Data on bulk density is required for MPs that are solidat room temperature.25If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).26If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).27If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).28Not required for salts.29Data must be provided in accordance with the "Product Composition" Section.(158.155)30Data must be provided in accordance with the "Description of Materials used to Produce the Product" Section.(158.160)Case # and Name:3026 Benzisothiazolin-3-oneDCI Number:PDCI-098901-27549Page 3 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSTGAI & EP = Technical Grade of the Active Ingredient and End-Use Product; EP; MP; TGAI = End Use Product; Manufacturing Use Product; Technical Grade Active Ingredient; TGAI or PAI =Technical Grade of the Active Ingredient or Pure Active Ingredient; EP = End Use Product [EP]; TGAI = Technical Grade Active Ingredient [TGAI]; EP; TGAI = End Use Product; Technical GradeActive Ingredient; EP & possibly TGAI = End- Use Product and possibly Technical Grade Active Ingredient31Data must be provided in accordance with the "Description of Production Process" Section.(158.162)32Data must be provided in accordance with the "Description of Formulation Process" Section.(158.165)33Data must be provided in accordance with the "Description of Formation of Impurities" Section(158.167)34Data must be provided in accordance with the "Preliminary Analysis" Section.(158.170)35Required for TGAIs and products produced by an integrated system.36If the TGAI cannot be isolated, data are required on the practical equivalent of the TGAI (i.e., if the active ingredient is either an acid, base or ionic form, and it is formulated into salts or esters,the concentration of the active ingredient in these products must be expressed in acid equivalent or active equivalent).37Data must be provided in accordance with the "Certified Limits" Section(158.175)38Data must be provided in accordance with the "Enforcement Analytical Method" Section.(158.180)39Not required if test material is a gas or highly volatile.40Not required if test material is corrosive to skin or has pH < 2 or >11.5; such a product will be classified as Toxicity Category I on the basis of potential dermal toxicity.41Not required if test material is a gas or highly volatile.42For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.43Not required if test material is corrosive to skin or has pH < 2 or > 11.5; such a product will be classified as Toxicity Category I on the basis of potential eye irritation effects.44Required if intended use of the antimicrobial pesticide product will involve purposeful application on human skin or will result in comparable exposure to the product (e.g. uses in swimming poolwater), or if the active ingredient of the product is known or expected to be metabolized differently by the dermal route of exposure than by the oral route, and a metabolite of the active ingredientis the toxic moiety. The EP shall also be tested if any component of the EP may increase dermal absorption of the active ingredient(s) or potentiate toxic or pharmacologic effects.45For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.Case # and Name:3026 Benzisothiazolin-3-oneDCI Number:PDCI-098901-27549Page 4 of 4[The following notes are referenced in column two (5. Study File) of the REQUIREMENTS STATUS AND REGISTRANT'S RESPONSE form.]Footnotes:Key:United States Environmental ProtectionAgency Washington, D.C. 20460FOOTNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREMENTSTGAI & EP = Technical Grade of the Active Ingredient and End-Use Product; EP; MP; TGAI = End Use Product; Manufacturing Use Product; Technical Grade Active Ingredient; TGAI or PAI =Technical Grade of the Active Ingredient or Pure Active Ingredient; EP = End Use Product [EP]; TGAI = Technical Grade Active Ingredient [TGAI]; EP; TGAI = End Use Product; Technical GradeActive Ingredient; EP & possibly TGAI = End- Use Product and possibly Technical Grade Active Ingredient46Required if repeated dermal exposure is likely to occur under conditions of use.47For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.48Required when the product consists of, or under conditions of use will result in, an inhalable material (e.g., gas, vapor, aerosol or particulates).49The 870 series studies for the MP and EP are intended to provide data on the acute toxicity of the product. Waivers for any orall of these studies may be granted when the applicant candemonstrate that the combination of inert ingredients is not likely to pose any significant human health risks. Where appropriate, the limit dose approach to testing is recommended.50Required when the product consists of, or under conditions of use will result in, an inhalable material (e.g. gas, volatile substances, or aerosol particulate).51Not required if test material is a gas or highly volatile.52For the six acute studies conducted with the end-use product, the test must be conducted using the product as formulated for sale and distribution. If the product is intended and labeled to bediluted for use, the applicant may also wish to conduct certain studies using the highest diluted concentration (i.e. lowest dilution rate) permitted by the labeling.United States Environmental ProtectionAgency Washington, D.C. 20460LIST OF ALL REGISTRANTS SENT THIS DATA CALL-IN NOTICECo. Nr.Company NameAgent ForAddressCity & StateZipCase # and Name:3026,Benzisothiazolin-3-oneTROY CHEMICAL COMPANYLIMITEDLEWIS & HARRISON122 C ST NW STE 740WASHINGTONDC20001365TROY CHEMICAL CORPPO Box 955 8 VREELAND ROADFLORHAM PARKNJ0793242005383TRUTEC INDUSTRIES INC4700 GATEWAY BLVDSPRINGFIELDOH4550268575INTERNATIONAL SPECIALTYPRODUCTS1361 ALPS RD.WAYNENJ074701529LANXESS CORPORATION111 RIDC PARK WEST DRIVEPITTSBURGHPA15275111239967DOW CHEMICAL CO., THETHE DOW CHEMICAL COMPANY1500 EAST LAKE COOK ROADBUFFALO GROVEIL60089464LONZA INC90 BOROLINE ROADALLENDALENJ074016836PROMCHEMIE AGMCDERMOTT, WILL & EMERY LLP600 13TH STREET, NWWASHINGTONDC2000580285ARCH CHEMICALS, INC.5660 NEW NORTHSIDE DRIVE, N.W., SUITE 1100ATLANTAGA303281258CLARIANT CORPORATIONLEWIS & HARRISON122 C ST NW STE 740WASHINGTONDC2000149403MAKHTESHIM-AGAN OF NORTHAMERICA INC4515 FALLS OF NEUSE RD, SUITE 300RALEIGHNC2760966222SANITIZED INCPO Box 2211 57 NEW MILFORD TKPE.NEW PRESTONCT0677702113090ROHM & HAAS CO100 INDEPENDENCE MALL WESTPHILADELPHIAPA191062399707CONTROL SOLUTIONS, INC.D. O'SHAUGHNESSY CONSULTING, INC.427 HIDE AWAY CIRCLECUB RUNKY4272953883THOR GMBHTHOR SPECIALTIES INC.56 QUARRY ROADTRUMBULLCT0661167071